[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351375-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351375-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-syngeneic-cell-lines-for-studying-high-risk-brafv600e-driven-colorectal-cancer-in-vivo","Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo","","Combining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade expanded treatment options for BRAFV600E-driven colorectal cancer, yet responses remain short-lived and heterogeneous. This study generated three syngeneic NaJa cell lines from peritoneal metastases derived from orthotopically transplanted organoids harboring BrafV600E, Trp53R172H, and Apc mutations. Using RNA-seq, whole-exome sequencing, and functional assays, the lines showed distinct differentiation states and differential sensitivity to RAF inhibitors encorafenib and exarafenib. Afatinib overcame RAF inhibitor resistance, and RAF inhibition reshaped antigen presentation, cytokines, and immunomodulatory factors. After retransplantation into syngeneic mice, all lines formed aggressive tumors with microenvironments matching their differentiation states.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-syngeneic-cell-lines-for-studying-high-risk-brafv600e-driven-colorectal-cancer-in-vivo/351375/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-syngeneic-cell-lines-for-studying-high-risk-brafv600e-driven-colorectal-cancer-in-vivo/351375.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of developing the NaJa cell lines in this study?","Question",{"text":63,"@type":64},"To provide immunocompetent syngeneic models that enable detailed study of tumor heterogeneity, drug resistance, and interactions among tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the three cell lines generated and what mutations do they carry?",{"text":68,"@type":64},"The study generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations.",{"name":70,"@type":61,"acceptedAnswer":71},"Which drugs were used to test targeted therapy responses and how was RAF inhibitor resistance addressed?",{"text":72,"@type":64},"The lines were tested against RAF inhibitors encorafenib and exarafenib, and resistance was overcome using the EGFR family inhibitor afatinib.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351375,1790193870,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-25-0599](https://doi.org/10.1158/2767-9764.CRC-25-0599)  OPEN ACCESS  \nNovel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo  \nJasmin Traichel1,2,3, Ariane Metzger3,4, Maria Walz1, Reinhild Feuerstein5, Nadine Wohlfeil1, Patrick Metzger4, Lisa Marx5, Clia Asdih1,3, Agnes Lindenthal1, Alina Seger1, Jule Schrimpf1, Luigi L. Nardella1, Silke Kowar1,4, Ian J. Frew2,6,7, Sebastian Halbach1,2, Rebecca Kesselring2,5, Melanie Boerries2,4, Ricarda Griffin1, and Tilman Brummer1,2,6  \n􀀶  \nABSTRACT  \nCombining anti-EGFR antibodies with BRAF/MEK/ERK pathway blockade opened new treatment options for BRAFV600E-driven colorectal cancer. Nevertheless, responses of these poor prognostic cancers are short-lived and heterogeneous, thereby highlighting the unmet need for novel concepts integrating targeted therapy and immuno-oncology. To this end, an immunocompetent mouse model with reliable disease onset and responding to clinically relevant drugs is essential but unavailable. In this study, we generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations and characterized their ground state and responses to targeted therapy compounds in detail by RNA sequencing, whole-exome sequencing, and various functional assays. Interestingly, these so-called NaJa lines displayed distinct differentiation states and responses to the clinically relevant RAF inhibitors (RAFi) encorafenib and exarafenib, thereby resembling the clinical heterogeneity  \nof BRAFV600E-driven colorectal cancer. RAFi resistance was overcome by the EGFR family inhibitor afatinib. RAFis also influenced the expression of the antigen presentation machinery, cytokines, and other immunomodulatory factors. Upon retransplantation into syngeneic mice, all NaJa lines established aggressive tumors with distinct tumor microenvironments matching their differentiation states. Thus, the NaJa lines provide a unique tool to study tumor heterogeneity, drug resistance, and the interplay between tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.  \nSignificance: We present three newly isolated syngeneic BRAFV600Edriven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.  \nIntroduction  \nColorectal cancer poses a significant global socioeconomic problem with an increasing prevalence ( 1) . Colorectal cancer represents a(n) (epi)genetically heterogeneous disease, and its various genomic alterations influence the course of disease, affect prognosis, and steer therapeutic regimen (2) . Approximately 10% of colorectal cancers carry mutations in the BRAF protooncogene, encoding the serine/threonine protein kinase BRAF, a major signal transducer in the RAS/RAF/MEK/ERK axis, or ERK pathway in short ( 1) .  \n1Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2German Cancer Consortium (DKTK), Partner site Freiburg, a partnership between DKFZ and Medical Center - University of Freiburg, Freiburg, Germany. 3Faculty of Biology, University of Freiburg, Freiburg, Germany. 4Institute of Medical Bioinformatics and Systems Medicine (IBSM), Faculty of Medicine, Medical Center-University of Freiburg, Freiburg, Germany. 5Department of General and Visceral Surgery, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 6Centre for Biological Signaling Studies BIOSS, University of Freiburg, Freiburg, Germany. 7Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation,  \nUnder physiologic conditions, this pathway becomes activated by a plethora of receptor tyrosine kinases (RTK), such as the EGFR, which ","cbCaifN5QRIxtmi8","https://ap.wps.com/l/cbCaifN5QRIxtmi8","pdf",41928901,"English","# Abstract\n# Significance\n# Introduction","[{\"question\":\"What is the main goal of developing the NaJa cell lines in this study?\",\"answer\":\"To provide immunocompetent syngeneic models that enable detailed study of tumor heterogeneity, drug resistance, and interactions among tumor, stroma, and immune cells in BRAFV600E-driven colorectal cancer.\"},{\"question\":\"How were the three cell lines generated and what mutations do they carry?\",\"answer\":\"The study generated three cell lines from peritoneal metastases originating from orthotopically transplanted organoids carrying BrafV600E, Trp53R172H, and Apc mutations.\"},{\"question\":\"Which drugs were used to test targeted therapy responses and how was RAF inhibitor resistance addressed?\",\"answer\":\"The lines were tested against RAF inhibitors encorafenib and exarafenib, and resistance was overcome using the EGFR family inhibitor afatinib.\"}]","Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer In Vivo | PDF",1790093878,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a0e0d2390f5d30702d1925236f5f93f.webp",983,1263,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00e629afd1cda7d68ffced9c8fd08629.webp",982,1262,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62dc714d4f564efd1deef6010bd6c581.webp",981,1261,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9321b7b2c48a610c86d817e211551d20.webp",980,1259]